ViennaLab Diagnostics GmbH

Avoid hypersensitivity reactions to the anti-HIV drug Abacavir by HLA-B*57:01 genotyping.

HLA-B*57:01 is a genetic risk factor for hypersensitivity reactions to abacavir, an antiretroviral drug used in HIV therapy. The HLA-B5701 RealFast™ Assay determines the presence or absence of HLA-B*57:01 alleles in patients.




  • Abacavir is used in antiretroviral combination therapy for the treatment of HIV-infected patients.
  • The HLA-B*57:01 allele, a variant of the human leukocyte antigen B (HLA-B) gene, is strongly associated with abacavir hypersensitivity. HLA-B*57:01 positive patients must be excluded from such treatment.
  • Screening of patients for the presence of HLA-B*57:01 before starting abacavir therapy reduces the incidence of hypersensitivity reactions (HSR).

pdf Productnote 03: HLA-B5701


ProductReg. Stat.REFUnit SizeIFUBrochure
HLA-B5701 RealFast™ Assay CE/IVD7-610
100 rxn
32 rxn


We use Matomo to analyze the access to our website. We pass on information about your use of our website to our partners for analysis. Our partners may combine this information with other data that you have provided to them or that they have collected as part of your use of the services. I agree.

Deny Allow